The North America Drug Eluting Stent Market would witness market growth of 7.2% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 3,399.3 thousand units, showcasing a growth of 6.9% (2019-2022).
Stents are employed in operations like coronary angioplasty. Percutaneous coronary interventions (PCI), other coronary angioplasty procedures, and the therapy of coronary artery disease involve drug-eluting stents (DES). Three components comprise a drug eluting stent: the stent platform, the polymer coating (which keeps the medication inside the stent), and the drug itself. The danger of acquiring artery diseases rises with the aging population, increasing the need for efficient treatment alternatives like drug eluting stents.
The prevalence of atherosclerosis, defined by plaque development in the arteries, has increased due to sedentary lifestyles and poor dietary practices. Heart attacks and strokes, among other cardiovascular disorders, are considerably exacerbated by this disease. Due to this growing public health hazard, drug eluting stents are becoming more popular among medical professionals as a preferred method of treating atherosclerosis.
Additionally, reducing patient problems and the number and length of hospital stays have received significant attention as the healthcare industry reforms to switch from the present fee-for-service model to a fee-for-value model. Particularly in interventional cardiology, there has been a considerable evolution in device technology, operator techniques, clinical safety, and efficacy. Huge strides have been made in treating coronary artery disease, and patients today live in the era of "stent implantation."
Canada has also seen many cases of heart disease in recent years. Approximately 1 in 12 (or 2.6 million) Canadian adults age 20 and over have been diagnosed with heart disease, and every hour, roughly 14 Canadian adults age 20 and over with this diagnosis pass away, according to 2017–2018 statistics from the Canadian Chronic Disease Surveillance System (CCDSS). Likewise, the aging population is also a concern. According to the Government of Canada, over 861,000 older adults, or more than twice as many as were found in the 2001 Census, were counted in the 2021 Census. With a 12% increase over 2016, the population of people aged 85 and beyond is one of the age groups with the most significant growth. At the moment, 2.3% of people are 85 years of age or older. The abovementioned factors will present lucrative prospects for drug eluting stents in North America.
The US market dominated the North America Drug Eluting Stent Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,570.1 million by 2030. The Canada market is experiencing a CAGR of 9.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.7% during (2023 - 2030).
Based on Application, the market is segmented into Coronary Artery Disease, and Peripheral Artery Disease. Based on Coating Type, the market is segmented into Polymer-based Coating (Non-biodegradable Polymers, and Biodegradable Polymers), and Polymer-free Coating (Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface). Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.), Cook Medical, Inc. (Cook Group), B. Braun Melsungen AG, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd and Alvimedica.
Stents are employed in operations like coronary angioplasty. Percutaneous coronary interventions (PCI), other coronary angioplasty procedures, and the therapy of coronary artery disease involve drug-eluting stents (DES). Three components comprise a drug eluting stent: the stent platform, the polymer coating (which keeps the medication inside the stent), and the drug itself. The danger of acquiring artery diseases rises with the aging population, increasing the need for efficient treatment alternatives like drug eluting stents.
The prevalence of atherosclerosis, defined by plaque development in the arteries, has increased due to sedentary lifestyles and poor dietary practices. Heart attacks and strokes, among other cardiovascular disorders, are considerably exacerbated by this disease. Due to this growing public health hazard, drug eluting stents are becoming more popular among medical professionals as a preferred method of treating atherosclerosis.
Additionally, reducing patient problems and the number and length of hospital stays have received significant attention as the healthcare industry reforms to switch from the present fee-for-service model to a fee-for-value model. Particularly in interventional cardiology, there has been a considerable evolution in device technology, operator techniques, clinical safety, and efficacy. Huge strides have been made in treating coronary artery disease, and patients today live in the era of "stent implantation."
Canada has also seen many cases of heart disease in recent years. Approximately 1 in 12 (or 2.6 million) Canadian adults age 20 and over have been diagnosed with heart disease, and every hour, roughly 14 Canadian adults age 20 and over with this diagnosis pass away, according to 2017–2018 statistics from the Canadian Chronic Disease Surveillance System (CCDSS). Likewise, the aging population is also a concern. According to the Government of Canada, over 861,000 older adults, or more than twice as many as were found in the 2001 Census, were counted in the 2021 Census. With a 12% increase over 2016, the population of people aged 85 and beyond is one of the age groups with the most significant growth. At the moment, 2.3% of people are 85 years of age or older. The abovementioned factors will present lucrative prospects for drug eluting stents in North America.
The US market dominated the North America Drug Eluting Stent Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,570.1 million by 2030. The Canada market is experiencing a CAGR of 9.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.7% during (2023 - 2030).
Based on Application, the market is segmented into Coronary Artery Disease, and Peripheral Artery Disease. Based on Coating Type, the market is segmented into Polymer-based Coating (Non-biodegradable Polymers, and Biodegradable Polymers), and Polymer-free Coating (Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface). Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.), Cook Medical, Inc. (Cook Group), B. Braun Melsungen AG, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd and Alvimedica.
Scope of the Study
Market Segments Covered in the Report:
By Application (Volume, Thousand Units, USD Million, 2019-2030)- Coronary Artery Disease
- Peripheral Artery Disease
- Polymer-based Coating
- Non-biodegradable Polymers
- Biodegradable Polymers
- Polymer-free Coating
- Micro Porous Surface
- Micro Structured Surface
- Slotted Tubular Surface
- Nanoporous Surface
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic PLC
- Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.)
- Cook Medical, Inc. (Cook Group)
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Lepu Medical Technology Co., Ltd
- Alvimedica
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. North America Drug Eluting Stent Market by Application
Chapter 5. North America Drug Eluting Stent Market by Coating Type
Chapter 6. North America Drug Eluting Stent Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic PLC
- Biosensors International Group, Ltd. (Blue Sail Medical Co., Ltd.)
- Cook Medical, Inc. (Cook Group)
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Lepu Medical Technology Co., Ltd
- Alvimedica
Methodology
LOADING...
